$37.820
+0.953 (+2.52%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
GMAB Prediction & Forecast by Similar Chart Analysis
Alphio's GMAB stock price prediction model matches the current Genmab A/S tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $37.83 (+0.02%). The 1-week path is $37.28 (-1.43%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy Genmab A/S Stock?
Genmab A/S (GMAB) is a good buy right now, trading at $37.07 with a forward P/E of 15.08, suggesting it is undervalued compared to its growth prospects. The recent positive results from the Phase 3 EPCORE DLBCL-2 trial indicate a 51% reduction in disease progression risk, which could significantly boost future sales. However, the stock faces risks from the recent failure of the Epcoritamab trial, which could impact market confidence and sales expectations, particularly given the 1.54% drop in after-hours trading following the news.
GMAB stock price ended at $37.82 on Thursday, after rising +2.52%
Genmab A/S (GMAB) last closed at $37.82, gaining +2.52%. These facts feed the 1-day and 1-week GMAB price prediction above.
Forecast Drivers
Genmab A/S (GMAB) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bearish
Seasonality
Bullish
SMA 20
Bullish
SMA 200
Bullish
Similar Chart Patterns
Stocks whose recent price path most closely matches GMAB, ranked by similarity.
Seasonality analysis for GMAB
Historically the probability of a positive October return for GMAB is 60.34%. September offers the highest probability of a positive month at 67.74%, while April is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
10-year price projections for GMAB
| Month | Min Price | Avg Price | Max Price | Potential ROI |
|---|---|---|---|---|
| Oct 2026 | $17.30 | $21.62 | $22.57 | -42.83% |
| Nov 2026 | $28.07 | $28.69 | $33.47 | -24.14% |
| Dec 2026 | $24.17 | $24.45 | $26.55 | -35.35% |
In 2026, Genmab A/S (GMAB) is projected to range from $17.30 to $33.47.
Genmab A/S 2026 monthly forecast
In Oct 2026, Genmab A/S is projected to average $21.62, with a low of $17.30 and high of $22.57.
In Nov 2026, Genmab A/S is projected to average $28.69, with a low of $28.07 and high of $33.47.
In Dec 2026, Genmab A/S is projected to average $24.45, with a low of $24.17 and high of $26.55.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.